Eli Lilly and Company

Indianapolis – October 19, 2026 -- Half of pediatric ulcerative colitis (UC) patients who responded to Eli Lilly's Omvoh (mirikizumab-mrkz) were in clinical remission at Week 52, meeting the primary endpoint of the Phase 3 SHINE-2 study. Lilly (NYSE: LLY) says Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC, and it plans to submit the data to global regulators for a potential label expansion.

Lilly reports 81% induction response and 50% remission at one year

In the single-arm, open-label study, 81% of patients achieved clinical response at Week 12. Among the 52 responders, ages 6 to 17, 50% reached clinical remission at Week 52. The results were presented as a late-breaking oral presentation at United European Gastroenterology (UEG) Week 2026.

Secondary outcomes at Week 52 in responders were:

Indianapolis – October 18, 2026 -- Eli Lilly and Company (NYSE: LLY) will present first Phase 1 data for its investigational FRα-targeting antibody-drug conjugate sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer (PSOC) at the European Society for Medical Oncology (ESMO) Congress, October 23–27 in Madrid, alongside updated data across lung, thyroid and breast cancer programs.

Sofe-M plus bevacizumab data in PSOC backs ongoing Phase 3 trial

Lilly will give a rapid oral presentation on the first Phase 1 results for Sofe-M combined with bevacizumab in PSOC. The company says the data support the ongoing Phase 3 clinical trial of Sofe-M in PSOC.

Indianapolis – October 15, 2026 -- Eli Lilly and Company (NYSE: LLY) will publish its third-quarter 2026 financial results on October 29, 2026, and will discuss the numbers on a conference call the same day.

Lilly schedules a 10 a.m. Eastern call for investors and media

The conference call begins at 10 a.m. Eastern time. Lilly will use it to detail the company's financial performance for the quarter with the investment community and media.

Lilly opens the live webcast to the general public

Investors, media and the general public can follow the call through a live webcast. Lilly will post the access link on its investor relations website, and a replay will be available there after the call ends.

The announcement gives no financial figures, guidance or earnings metrics ahead of the October 29 release.

Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.

In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.

New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.

Atria-coordinated coalition unites pharma, tech and the UN behind brain health delivery

The International Brain Health Coalition (IBC), coordinated by the Atria Research and Global Health Institute (ARGHI), brings together patients, multilateral institutions including the United Nations, and organizations spanning medicine, technology, and finance. Collaborators include Eli Lilly and Company, Bristol Myers Squibb, Microsoft, the Royal Bank of Canada, the American Heart Association, UN Women, Western University, and the AI-Mind Institute in Norway.

Indianapolis – October 02, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), clearing the non-covalent BTK inhibitor as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion.

Phase 3 trial data show an 80% reduction in disease progression risk

The approval rests on the BRUIN CLL-313 trial, which randomized 282 treatment-naïve patients 1:1 to pirtobrutinib or bendamustine plus rituximab (BR) chemoimmunotherapy. At a median follow-up of 28 months, pirtobrutinib cut the risk of disease progression by 80% versus BR (HR=0.20; 95% CI, 0.11–0.37; p0.0001). Median progression-free survival was not yet reached in the pirtobrutinib arm, compared with 33.5 months for BR.

New York – – October 02, 2026 -- The American Institute of Chemical Engineers (AIChE) will honor 16 chemical engineering leaders with its 2026 Institute and Board of Directors' Awards, the organization's highest professional recognition, at the AIChE Annual Meeting in Minneapolis, Minnesota, November 8-12.

Industry and academic sponsors back top honors

Dr. Nicholas Peppas of The University of Texas at Austin will receive the Van Antwerpen Award for Service to AIChE, sponsored by Dow. Dr. Liang-Shih Fan of The Ohio State University earns the Founders Award for lifetime contributions to the field. Dr. Rong Yang of Cornell University will receive the Allan P. Colburn Award, sponsored by DuPont de Nemours, for publications by a young member.

Indianapolis – – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 therapy Foundayo (orforglipron) reduced cardiovascular death risk by 53% and all-cause death risk by 57% compared with insulin glargine in the Phase 3 ACHIEVE-4 trial, the largest and longest study of the medicine in type 2 diabetes to date.

Foundayo meets non-inferiority bar on major cardiovascular events

Among 2,749 participants randomized across 16 countries including the U.S., Germany, India, Brazil and South Korea, Foundayo showed a 16% lower risk of MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) versus insulin glargine, with a hazard ratio of 0.84 (95.0% CI: 0.59 to 1.20), meeting the prespecified non-inferiority threshold. The risk of MACE-3 (cardiovascular death, heart attack or stroke) was 23% lower (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13).

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

Highest dose delivers weight loss up to 23.4% in heavier patients

Across the three tested doses, participants lost an average of 29.8 lbs (12.7%) at 4 mg, 45.4 lbs (19.1%) at 9 mg, and 49.6 lbs (20.8%) at 12 mg. Among patients with a baseline BMI of 35 or higher, the 12 mg dose produced an average loss of 60.8 lbs (23.4%), with 59.5% of all 12 mg participants no longer classified as having obesity by trial end.